- Home
- V vs JNJ Comparison
V vs JNJ Comparison
Compare V & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | V | JNJ |
|---|---|---|
| Founded | 1958 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 676.2B | 589.2B |
| IPO Year | 2007 | 2003 |
Fundamental Metrics
Financial Performance| Metric | V | JNJ |
|---|---|---|
| Price | $321.32 | $247.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 17 |
| Target Price | ★ $399.71 | $227.29 |
| AVG Volume (30 Days) | 7.4M | ★ 7.7M |
| Earning Date | 04-30-2026 | 04-21-2026 |
| Dividend Yield | 0.84% | ★ 2.09% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 11.03 |
| Revenue | ★ $21,846,000,000.00 | N/A |
| Revenue This Year | $13.81 | $6.63 |
| Revenue Next Year | $10.31 | $7.21 |
| P/E Ratio | $30.09 | ★ $22.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $299.00 | $141.50 |
| 52 Week High | $375.51 | $251.71 |
Technical Indicators
Market Signals| Indicator | V | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 69.37 |
| Support Level | $304.57 | $201.37 |
| Resistance Level | $350.70 | N/A |
| Average True Range (ATR) | 7.19 | 3.81 |
| MACD | 0.78 | -0.59 |
| Stochastic Oscillator | 59.83 | 70.44 |
Price Performance
Historical ComparisonAbout V Visa Inc.
Visa is the largest payment processor in the world. In fiscal 2025, it processed almost $17 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.